SG11202111193UA - Methods and compositions for targeted protein degradation - Google Patents

Methods and compositions for targeted protein degradation

Info

Publication number
SG11202111193UA
SG11202111193UA SG11202111193UA SG11202111193UA SG11202111193UA SG 11202111193U A SG11202111193U A SG 11202111193UA SG 11202111193U A SG11202111193U A SG 11202111193UA SG 11202111193U A SG11202111193U A SG 11202111193UA SG 11202111193U A SG11202111193U A SG 11202111193UA
Authority
SG
Singapore
Prior art keywords
compositions
methods
protein degradation
targeted protein
targeted
Prior art date
Application number
SG11202111193UA
Other languages
English (en)
Inventor
Weiwen Ying
Long Ye
Kevin Foley
Original Assignee
Ranok Therapeutics Hangzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranok Therapeutics Hangzhou Co Ltd filed Critical Ranok Therapeutics Hangzhou Co Ltd
Publication of SG11202111193UA publication Critical patent/SG11202111193UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11202111193UA 2019-04-09 2020-04-08 Methods and compositions for targeted protein degradation SG11202111193UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/081919 WO2020206608A1 (en) 2019-04-09 2019-04-09 Methods and compositions for targeted protein degradation
PCT/CN2020/083647 WO2020207395A1 (en) 2019-04-09 2020-04-08 Methods and compositions for targeted protein degradation

Publications (1)

Publication Number Publication Date
SG11202111193UA true SG11202111193UA (en) 2021-11-29

Family

ID=72750919

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111193UA SG11202111193UA (en) 2019-04-09 2020-04-08 Methods and compositions for targeted protein degradation

Country Status (12)

Country Link
US (2) US20220162228A1 (de)
EP (2) EP3952914A4 (de)
JP (2) JP2022528568A (de)
KR (1) KR20220007055A (de)
CN (2) CN113924123A (de)
AU (2) AU2020256814A1 (de)
BR (1) BR112021020285A2 (de)
CA (2) CA3136370A1 (de)
IL (1) IL287082A (de)
MX (1) MX2021012423A (de)
SG (1) SG11202111193UA (de)
WO (3) WO2020206608A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230414723A1 (en) * 2020-10-26 2023-12-28 Trustees Of Tufts College Enhanced hyt-induced protein degradation using lipid nanoparticle delivery
CN112979657A (zh) * 2021-02-03 2021-06-18 福建医科大学 一种靶向降解Hsp90蛋白的化合物及其制备方法与应用
CN115232030A (zh) * 2021-04-23 2022-10-25 中国医学科学院药物研究所 芳基脲类化合物及其制法和药物用途
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
AU2022362494A1 (en) * 2021-10-14 2024-05-23 Cullgen (Shanghai), Inc. Modified proteins and protein degraders
CN114907386B (zh) * 2022-03-11 2023-03-31 山东大学 一种hemtac小分子降解剂及其应用
WO2024037527A1 (en) * 2022-08-16 2024-02-22 Beijing Neox Biotech Limited Btk degrading compounds
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012075456A1 (en) * 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
EP3608317A1 (de) * 2012-01-12 2020-02-12 Yale University Verbindungen und verfahren für den verstärkten abbau von gezielten proteinen und anderen polypeptiden durch eine e3-ubiquitinligase
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
WO2014128070A1 (de) * 2013-02-22 2014-08-28 Bayer Pharma Aktiengesellschaft Pyrrolo- und pyrazolo-triazolodiazepine als bet-proteininhibitoren zur behandlung von hyper-proliferativen erkrankungen
EP2958923A1 (de) * 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituierte pyrrolo- und pyrazolo-diazepine
WO2015038649A1 (en) * 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3131586A4 (de) * 2014-03-18 2017-10-25 Madrigal Pharmaceuticals, Inc. Zielgerichtete therapeutika
US20170136085A1 (en) * 2014-05-29 2017-05-18 Synta Pharmaceuticals Corp. Targeted therapeutics
PL3458101T3 (pl) * 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
CN108129484B (zh) * 2017-12-19 2021-04-27 郭守东 杂芳环衍生物
CN108084193A (zh) * 2017-12-19 2018-05-29 郭守东 一种brd4蛋白抑制剂

Also Published As

Publication number Publication date
CN113939516A (zh) 2022-01-14
AU2020256814A1 (en) 2021-12-02
CN113924123A (zh) 2022-01-11
EP3953359A1 (de) 2022-02-16
AU2020256600A1 (en) 2021-12-02
WO2020207396A1 (en) 2020-10-15
CA3136372A1 (en) 2020-10-15
EP3953359A4 (de) 2023-07-19
JP2022528568A (ja) 2022-06-14
MX2021012423A (es) 2022-01-19
WO2020207395A1 (en) 2020-10-15
WO2020206608A1 (en) 2020-10-15
BR112021020285A2 (pt) 2021-12-14
US20220162228A1 (en) 2022-05-26
CA3136370A1 (en) 2020-10-15
US20220168427A1 (en) 2022-06-02
EP3952914A4 (de) 2023-05-10
KR20220007055A (ko) 2022-01-18
IL287082A (en) 2021-12-01
JP2022528767A (ja) 2022-06-15
EP3952914A1 (de) 2022-02-16

Similar Documents

Publication Publication Date Title
IL273948A (en) Preparations and methods for the selective degradation of proteins
IL287082A (en) Methods and preparations for targeted unloading of proteins
EP3897631A4 (de) Gezielter proteinabbau
EP3710002A4 (de) Degrader und degrone für gezielten proteinabbau
IL276464A (en) Methods and preparations for administering therapeutic protein
IL280134A (en) Anti-CD112R preparations and methods
GB201710620D0 (en) Targeted protein degradation
EP3826666A4 (de) Zusammensetzungen und verfahren zur behandlung von nrp2-assoziierten erkrankungen
EP4037711A4 (de) Zusammensetzungen und verfahren mit anti-nrp2-antikörpern
IL285886A (en) Preparations and methods for the treatment of laminopathy
IL288024A (en) Methods and preparations for the prevention of type 1 diabetes
EP3790557A4 (de) Zusammensetzungen und verfahren zur verbesserung der strangvorspannung
SG11202104448WA (en) Compositions and methods
GB202017593D0 (en) Compositions and methods and uses relating thereto
IL290325A (en) Biopharmaceutical preparations and related methods
IL292872A (en) Preparations and methods for immunotherapy
EP4013445A4 (de) Therapeutische proteinzusammensetzungen und verfahren
IL285796A (en) Methods and preparations for the treatment of cancer
GB201819987D0 (en) Methods and compositions
GB201817444D0 (en) Methods and compositions
EP3836941A4 (de) Verfahren und zusammensetzungen zur behandlung von mukositis
EP3781945A4 (de) Zusammensetzungen und verfahren zur behandlung von endometriose
SG11202108262VA (en) Bacterialcidal methods and compositions
GB2579687B (en) Composition and method
GB201914777D0 (en) Composition and method